PCM
CDIO icon

Prelude Capital Management’s Cardio Diagnostics CDIO Stock Holding History

Prelude Capital Management’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,033
Closed -$41.1K – 1151
2023
Q3 		$41.1K Buy
4,033
+366
+10% +$8.8K ﹤0.01% 1055
2023
Q2 		$131K Buy
+3,667
New +$207K 0.01% 903

Other funds holding CDIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return

Prelude Capital Management's CDIO Position: Q4 2023 in Review

Prelude Capital Management sold out of Cardio Diagnostics (CDIO) in Q4 2023, closing a stake of 4,033 shares — an estimated $41.1K sold.

Prelude Capital Management first reported a position in CDIO in Q2 2023 and held it in 2 quarters. The position peaked at $131K in Q2 2023. 14 funds tracked by Wall St. Rank hold CDIO as of Q4 2023.

  • Prelude Capital Management reported no remaining Cardio Diagnostics position as of Q4 2023 after selling out during the quarter.
  • Prelude Capital Management sold 4,033 Cardio Diagnostics shares in Q4 2023, an estimated $41.1K.
  • Prelude Capital Management first reported a position in Cardio Diagnostics in Q2 2023 and held it in 2 quarters.
  • Prelude Capital Management's Cardio Diagnostics position peaked at $131K in Q2 2023.
  • 14 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.